Literature DB >> 25949980

Ciprofloxacin induced bullous fixed drug reaction: three case reports.

Pragya A Nair1.   

Abstract

Cutaneous adverse drug reactions (ADRs) are seen in about 1-2% cases. Fixed drug reaction (FDR) is responsible for about 10% of all ADRs. It is a delayed type of hypersensitivity reaction that occurs as lesions recurs at the same skin site due to repeated intake of an offending drug. The most common drugs causing fixed drug eruption (FDE) are analgesics, antibiotics, muscle relaxants and anticonvulsants. FDE due to ciprofloxacin has been reported earlier also, but bullous variant of FDR is rare. We hereby report three case reports of bullous FDR caused due to ciprofloxacin.

Entities:  

Keywords:  Bullous; ciprofloxacin; fixed drug reaction

Year:  2015        PMID: 25949980      PMCID: PMC4408714          DOI: 10.4103/2249-4863.154673

Source DB:  PubMed          Journal:  J Family Med Prim Care        ISSN: 2249-4863


Introduction

Ciprofloxacin is a widely used quinolone antibiotic since 1986. It is used against both Gram-positive and Gram-negative organism. It has excellent tissue penetration in the skin and soft tissue infections and is a well-tolerated drug. Side effects reported are nausea, abdominal discomfort, headache, dizziness. Cutaneous adverse drug reactions (ADRs) are seen in about 1–2% of treated patients.[1] Urticaria angioedema, maculopapular exanthem, and photosensitivity are the most frequently documented cutaneous adverse reactions.[2] Fixed drug eruption (FDE) due to ciprofloxacin has been reported earlier.[3456] More severe reaction like Steven–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) can also occur with ciprofloxacin.[78] We hereby report three case reports of bullous fixed drug reaction (FDR) caused due to ciprofloxacin.

Case Report

All the three patients presented with a history of lesions over the body after consuming ciprofloxacin. Symptoms in the form of burning sensations and itching were experienced by all of them. Lesions developed at different time duration after consumption of drugs but within 1-week duration [Table 1], [Figures 1-3a and b].
Table 1

Clinico-epidemiological details of patients

Figure 1

Multiple well defined erythematous to violaceous patches with bullous lesion in few over the back

Figure 3

(a and b) Well-defined hyperpigmented patch with crusting over lips and genitals

Clinico-epidemiological details of patients Multiple well defined erythematous to violaceous patches with bullous lesion in few over the back Hyperpigmented patches with bullous lesions over base of left thumb (a and b) Well-defined hyperpigmented patch with crusting over lips and genitals All the patients were stable vitally. Routine complete blood count, renal function test and chest-X-ray were normal in all patients. All were treated with oral steroids in tapering dose that is, started with 40 mg/day of prednisolone, antihistamines, local soframycin and topical steroids were added in hyperpigmented lesions. All were given drug list that contained list of drugs that leads to FDR. They were advised to avoid all those group of drugs in the future.

Discussion

The term FDE was first introduced by Brocq in 1894.[9] It is a delayed type of hypersensitivity reaction that occurs as lesions recurs at the same skin site due to repeated intake of an offending drug.[10] The exact mechanism for this FDE is still unclear but, it has been postulated that FDE is due to a delayed classical type IVc hypersensitivity reaction mediated by CD8+ T cells.[11] The drug binds with basal keratinocytes and stimulates the inflammatory process by causing the release of lymphokines, mast cell and antibodies, which in turn causes damage to basal cell. CD8+ on activation causes release of interferon and cytotoxic granules.[12] A genetic susceptibility to develop a FDE with an increased incidence of human leukocyte antigen-B22 is also a possibility,[13] which is seen in our case-1 where patient had family history of drug reaction, while other cases had negative family history. The peak incidence is usually between 21 and 40 years of age. Males have slightly higher predilection than female counterparts. It mostly occurs in patients who intermittently receive the causative agent rather than on continuous administration. It also tends to occur with other drugs similar in structure to the causative agent. The list of causative drugs is long, including nonnarcotic analgesics, antibacterial agents, antifungal agents, antipsychotics, other miscellaneous drugs. Even ultraviolet radiation, emotional and psychiatric factors, heat, menstrual abnormalities, pregnancy, fatigue, cold, and undue effort can lead to FDE. Furthermore, it is difficult to pinpoint a culprit drug in subsequent episodes considering cross and polysensitivity.[9] Ciprofloxacin was a considerable offender in 4.7%, in one case series[14] with all males similar to our cases. Norfloxacin-induced FDE has been reported less frequently and may have cross-sensitivity with ciprofloxacin.[5] Fixed drug eruption presents mainly as sharply marginated, round or oval itchy plaques of erythema and edema becoming dusky violaceous or brown and sometimes vesicular or bullous lesions on the lip, hip, sacrum, or genitalia.[15] Most of the reactions occur within 30 min to 1-day of drug exposure.[16] Subsequent reexposure to the medication results in a reactivation of the site, with inflammation occurring within 30 min to 16 h.[17] The lesions may be solitary or multiple. The most common sites are the genitalia in males and the extremities in females. Several variants of FDE have been described, based on their clinical features and distribution of lesions[18] including pigmented, generalized,[19] linear, nonpigmenting, bullous, eczematous, urticarial erythema dyschromicum perstans, vulvitis, psoriasiform or cellulitis. Lesions may persist from days to weeks and then fade slowly to residual oval hyperpigmented patches.[20] The reactivation of old lesions also may be associated with the development of new lesions at other sites. The severity of reactions in FDE may increase after repeated exposures to the drug and very rarely progress to a clinical state called generalized bullous FDE, which is seen in case-1. It may be clinically misdiagnosed as SJS or TEN.[19] In generalized bullous FDE, the disease onset is within hours after the drug exposure. A diagnostic hallmark is the reappearance of the lesions over the previously affected sites, when the offending drug is reused. Mucosal sites are usually spared as in our case-1 but can be involved as seen in case-2 and 3. Histologically, FDE is characterized by marked basal cell hydropic degeneration with pigmentary incontinence. Scattered keratinocyte necrosis with eosinophilic cytoplasm and pyknotic nucleus (civatte bodies) are seen in the epidermis. Infiltration of lymphocytes, histiocytes, and neutrophil polymorphs is evident in the upper dermis.[21] Rechallenging the patient to the suspected offending drug is the only known test to possibly discern the causative agent, but that is unethical and not advisable. Therefore, certain causality assessment scales regarding drug reaction have been described like the Naranjo ADR probability scale, WHO-Uppsala Monitoring Centre causality assessment system and Hartwig scale.[222324] Treatment includes stopping the offending drug with oral and topical steroids, emollients, and oral antihistamines. Though usually not fatal, FDE can cause enough cosmetic embarrassment especially when they recur on the previously affected sites leaving behind residual hyperpigmentation.

Conclusion

Pharmacovigilance for detecting and diagnosing ADR by practicing physicians, general practitioners and family physicians is an essential armament of their clinical acumen. It is also important to report ADRs, which can help detect and prevent drug reactions and in turn decrease the cost of treatment. Ciprofloxacin is commonly used antibiotic, it is important for prescribing physician to keep in mind that it can also lead to bullous FDR.
  18 in total

Review 1.  Pathophysiology of fixed drug eruption: the role of skin-resident T cells.

Authors:  Tetsuo Shiohara; Yoshiko Mizukawa; Yuichi Teraki
Journal:  Curr Opin Allergy Clin Immunol       Date:  2002-08

2.  Ciprofloxacin-induced bullous fixed drug eruption.

Authors:  S K Bose
Journal:  Indian J Dermatol Venereol Leprol       Date:  1995 Jul-Aug       Impact factor: 2.545

3.  A three-year-analysis of fixed drug eruptions in hospital settings in France.

Authors:  Nesrine Brahimi; Emilie Routier; Nadia Raison-Peyron; Anne-Fleur Tronquoy; Caroline Pouget-Jasson; Stéphanie Amarger; Laurent Machet; Emmanuelle Amsler; Antoine Claeys; Bruno Sassolas; Dominique Leroy; Anne Grange; Alain Dupuy; Nadège Cordel; Jean-Marie Bonnetblanc; Brigitte Milpied; Marie-Sylvie Doutre; Marie-Thérèse Guinnepain; Annick Barbaud; Olivier Chosidow; Jean-Claude Roujeau; Bénédicte Lebrun-Vignes; Vincent Descamps
Journal:  Eur J Dermatol       Date:  2010-05-27       Impact factor: 3.328

Review 4.  Fixed drug eruption (FDE): changing scenario of incriminating drugs.

Authors:  Virendra N Sehgal; Govind Srivastava
Journal:  Int J Dermatol       Date:  2006-08       Impact factor: 2.736

5.  Ciprofloxacin-induced generalized bullous fixed drug eruption.

Authors:  Simin Ada; Sema Yilmaz
Journal:  Indian J Dermatol Venereol Leprol       Date:  2008 Sep-Oct       Impact factor: 2.545

6.  Fixed drug eruption induced by ciprofloxacin followed by ofloxacin.

Authors:  A Kawada; M Hiruma; K Morimoto; A Ishibashi; H Banba
Journal:  Contact Dermatitis       Date:  1994-09       Impact factor: 6.600

7.  Fixed drug eruption due to ciprofloxacin.

Authors:  S Dhar; V K Sharma
Journal:  Br J Dermatol       Date:  1996-01       Impact factor: 9.302

8.  Drug related clinical pattern in fixed drug eruption.

Authors:  E Ozkaya-Bayazit; H Bayazit; G Ozarmagan
Journal:  Eur J Dermatol       Date:  2000-06       Impact factor: 3.328

Review 9.  Quinolone hypersensitivity.

Authors:  Paolo Campi; Werner J Pichler
Journal:  Curr Opin Allergy Clin Immunol       Date:  2003-08

Review 10.  Fixed drug eruption: pathogenesis and diagnostic tests.

Authors:  Tetsuo Shiohara
Journal:  Curr Opin Allergy Clin Immunol       Date:  2009-08
View more
  2 in total

1.  Ofloxacin Induced Angioedema: A Rare Adverse Drug Reaction.

Authors:  Gautam Rawal; Sankalp Yadav; Raj Kumar; Umar Rasool Wani
Journal:  J Clin Diagn Res       Date:  2016-11-01

Review 2.  Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity.

Authors:  Katherine C Konvinse; Elizabeth J Phillips; Katie D White; Jason A Trubiano
Journal:  Curr Opin Infect Dis       Date:  2016-12       Impact factor: 4.915

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.